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Balloon commissurotomyAbstract Objective: To evaluate the ability of BNP to identify a subset of patients with
asymptomatic signiﬁcant rheumatic MS, who get symptoms on stress exercise testing.
Methods: Seventy asymptomatic patients with signiﬁcant rheumatic MS (MVA 61.5 cm2) were
included in the study. All patients underwent resting echo-Doppler study, exercise echocardiogra-
phy and BNP level assessment pre- and one week post-balloon dilatation (for group I patients
who had PMC).
Patients were divided into two groups. Group I included 33 patients who became symptomatic on
exercise and had low exercise capacity. Group II included 37 patients who were asymptomatic on
exercise and had reasonable exercise capacity.
Results: BNP level in group I was 92 ± 12 compared to 40 ± 10 pg/ml in group II, P< 0.001.
Post PMC, BNP in group I signiﬁcantly decreased (92 ± 12, compared to 31 ± 9 pg/dl,
P< 0.001). LA dimension was signiﬁcantly different between both groups (50 ± 2.9 in group I
compared to 46 ± 3.1 mm in group II, P< 0.001). Post-exercise SPAP was 72 ± 12 in group I
compared to 46 ± 13 mmHg in group II, P< 0.001. Post-exercise MV gradient was 28 ± 9
270 A. El Zayatcompared to 20 ± 12 mmHg, P= 0.002. BNP signiﬁcantly correlated with post-exercise SPAP
(r= 0.635; P< 0.001). Area under the ROC curve for BNP as a predictor of low exercise capacity
and development of symptoms on exercise was 0.98 [CI 95% 0.96–1.0]. When using a cutoff value of
55 pg/mL for BNP, sensitivity was 93.9% and speciﬁcity was 91.9%.
Conclusion: BNP may be used to approach asymptomatic patients with signiﬁcant MS. BNP may
identify a subset of patients with exercise-induced clinical and echo-Doppler criteria that meet the
contemporary guidelines for intervention.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Current European Society of Cardiology (ESC) guidelines for
management of valvular heart diseases (2012), recommend
doing percutaneous mitral commissurotomy (PMC) for
patients with clinically signiﬁcant mitral stenosis (MS) (mitral
valve area 61.5 cm2) with suitable valve scores if patients are
symptomatic. In asymptomatic patients, intervention is
justiﬁed for those who become symptomatic on exercise testing
and those who had low exercise capacity [achieve <5 Meta-
bolic Equivalents (METs)].1
Rheumatic valvular heart diseases continue to be a major
health problem in developing countries. Mitral stenosis is
one of the most frequently encountered rheumatic valvular
heart disease affections.2,3 Regular follow up for patients with
signiﬁcant mitral stenosis is crucial to take the proper decision
of intervention in the proper time (either surgical replacement
or alternatively balloon commissurotomy if the valve morphol-
ogy is suitable). It is frequently encountered that rheumatic
MS patients describe equivocal symptoms. Due to the long
latent period between onset of the initial rheumatic valvular
affection and development of signiﬁcant mitral stenosis, it is
difﬁcult for the treating physician to truly identify patients
with symptoms that could be attributed to either hemodynam-
ically signiﬁcant stenosis or non cardiac dyspnea. Some
patients have a sedentary life style that may result in physical
deconditioning and subsequently exertional symptoms. On the
other hand, other patients who are considered asymptomatic
adapt their level of exertion and thereby do not get symptoms.
Symptomatic status is mainly subjective, and hence a better
risk stratiﬁcation objective tool is required to be implemented
in regular follow up of rheumatic MS patients.4
Several studies have reported an association between
natriuretic peptides and severity of mitral stenosis.5 Other
studies have remarked a signiﬁcant drop of Brain Natriuretic
Peptide (BNP) post PMC.5,6
Thepredominant cardiac sourceofAtrialNatriureticPeptide
(ANP)istheatria,whiletheventriclesarethemainsourceofBNP,
although both can be synthesized in either chamber.7–10 Both
ANPandBNParereleasedintothecirculationfollowingprimarily
myocytestretch.ANPreleaseismorecloselyrelatedtoincreasedleft
atrialpressurewhileBNPreleaseismoredependentonincreasedleft
ventricularpressure.11,12,10,13–16
In previous studies, a strong correlation between plasma
BNP level and left atrial area suggested atrial secretion of
BNP in MS. This was supported by evidence for synthesis of
BNP by atrial myocytes in response to chronic increase in wall
stress and co-storage of BNP with ANP in atrial granules.14
In valvular heart diseases, BNP serum level was found to be
related to functional class and prognosis, particularly in aorticstenosis (AS) and mitral regurgitation (MR). In patients with
chronic asymptomatic MR, several studies suggested the value
of elevated BNP levels and a change in BNP as predictors of
outcome. A cut-off BNP value P105 pg/ml determined in a
derivation cohort was prospectively validated in a separate
cohort and helped to identify asymptomatic patients at higher
risk of developing heart failure, LV dysfunction or death on
mid-term follow-up.17 Another study found that low-plasma
BNP had a high negative predictive value and might be helpful
for the follow-up of asymptomatic organic MR patients.18
The aim of our study was to evaluate the ability of a single
baseline BNP level assessment to truly identify an important
subset of asymptomatic clinically-signiﬁcant rheumatic MS
patients (with suitable valve scores for PMC) whose exercise
stress criteria (clinical and echo-Doppler) meet the ESC con-
temporary guidelines for intervention.
2. Patients and methods
In this single center study, seventy asymptomatic patients with
clinically signiﬁcant rheumatic mitral stenosis (MVA 61.5 cm2
and >1 cm2) were prospectively included. All patients had
suitable mitral valve scores for percutaneous dilation (mitral
valve scores of 68). All patients had a resting systolic pulmon-
ary artery pressure <50 mmHg. All patients underwent
treadmill exercise testing and post-exercise echo-Doppler
study. Patients were divided into two groups based on symp-
tomatic status on exercise and exercise capacity. Group I
included 33 patients who were symptomatic on exercise and
had low exercise capacity (<5 METs).19 Group II included
37 patients who were asymptomatic on exercise and had a rea-
sonable exercise capacity (>5 METs).
Exclusion criteria were poor echocardiography window,
signiﬁcant renal impairment, presence of ischemic heart disease
by history or resting wall motion abnormality (WMA) on
echo-Doppler study, previous cardiac surgery or valve inter-
vention, coexistent heart muscle disease or other valvular
lesion (if graded more than mild) or inability to exercise
(inability to walk on treadmill).
This study was carried out in the Cardiology Department,
Faculty of Medicine, Zagazig University Hospitals, in the
period from July 2011 to November 2013. All patients gave
an informed consent to participate in the study.
2.1. BNP measurement
All samples were collected by veni-puncture into EDTA tubes
within 2 h of obtaining the baseline echocardiogram and one
week after PMC (for group I). The blood samples were kept
at room temperature and analyzed within 4 h of sampling
Table 1 Demographic and resting echo-Doppler characteris-
tics in the two groups.
Group I
(n= 33)
Group II
(n= 37)
P value
Age (years) 29 ± 10.1 32 ± 9.3 0.33
Males (n, %) 10 (30.3%) 12 (32.4%) 0.84
Systolic blood pressure 115 ± 13 118 ± 11 0.32
Diastolic blood pressure 65 ± 5 68 ± 7 0.44
Beta-blockers (n, %) 12 (36.4%) 10 (27%) 0.40
Loop diuretics (n, %) 20 (60.6%) 18 (48.6%) 0.31
Atrial ﬁbrillation (n, %) 18 (54.5%) 22 (59.4%) 0.74
Resting echocardiographic ﬁndings
LVEF (%) 59 ± 7 63 ± 9.1 0.14
Left atrial dimension (mm) 50 + 2.9 46 + 3.1 <0.001
Right ventricle (mm) 33.2 33.8 0.36
MV area(cm2) 1.29 ± 0.2 1.33 ± 0.1 0.31
Mean MV gradient (mmHg) 9 ± 3.2 10 ± 2.4 0.26
Systolic PAP (mmHg) 33 ± 12.3 35 ± 8.4 0.53
LVEF: left ventricular ejection fraction; MV: mitral valve; SPAP:
systolic pulmonary artery pressure.
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analysis, each tube was inverted several times to ensure homo-
geneity. The BNP assay was a sandwich immuno-assay that
consisted of a disposable device to which EDTA-anticoagulat-
ed whole blood or plasma was added. The triage meter was
used to measure the BNP concentration by detecting a ﬂuores-
cent signal that reﬂected the amount of BNP in the sample, the
cells were separated from the plasma by a ﬁlter, and the plasma
containing BNP entered a reaction chamber that contained
ﬂuorescent-tagged BNP antibodies to form a reaction mixture.
The reaction mixture was incubated for 2 min and then
migrated through the diagnostic lane by capillary action to a
zone of immobilized antibody that would bind the desired
BNP-ﬂuorescent antibody complex. The unbound ﬂuorescent
antibodies were washed away by excess sample ﬂuid. After
15 min, the device was placed in a Triage meter, which mea-
sured the ﬂuorescence intensity of the BNP assay zone. The
Triage meter then correlated the ﬂuorescence measurement
to BNP concentration by use of an internal calibration curve.
The assay was completed in 15 min.20
2.2. Baseline echocardiography study
All patients underwent resting echocardiography study using
SONOS 5500 machine (Philips technologies). The mitral valve
area (MVA) was calculated using pressure half time and direct
planimetry and the median MVA was calculated. The Wilkins
scores for MV suitability for PMC were calculated. This scor-
ing system assigns a point value from 1 to 4 for each of (1)
valve calciﬁcation, (2) leaﬂet mobility, (3) leaﬂet thickening,
and (4) disease of the subvalvular apparatus.21 By tracing the
continuous wave Doppler signal across the mitral valve, mean
transmitral pressure gradients were obtained. Left atrial
dimensions were obtained from the long axis parasternal view
using the m-mode. Systolic pulmonary artery pressure (SPAP)
was obtained using the simpliﬁed Bernoulli equation (the peak
tricuspid regurgitation (TR) jet was added to an estimate of
right atrial pressure obtained by imaging the inferior vena
cava). The left ventricular ejection fraction was measured from
the apical four-chamber view using the modiﬁed Simpson’s
rule.22,23 All values were obtained by averaging three cycles
(ﬁve in cases of atrial ﬁbrillation). All data were analyzed by
a single operator who was blind to patients’ symptomatic
status and BNP values.
2.3. Exercise treadmill test and post-exercise echo-Doppler
study
Symptom-limited treadmill test was done using a modiﬁed
Bruce protocol. Continuous 12 lead ECG monitoring and
blood pressure checking at three minutes interval were done.
Indications to stop treadmill were signiﬁcant arrhythmia, sig-
niﬁcant dyspnea, and fatigue or upon patient’s request. An
experienced cardiologist supervised the test.24
Within one minute of peak exercise, formal echo-Doppler
study was done with special emphasis on the apical four-
chamber view with continuous wave Doppler across mitral
valve for mean pressure gradient and the tricuspid valve for tri-
cuspid jet velocity and assessment of systolic pulmonary artery
pressure. Treadmill exercise test and post-treadmill
echocardiogram assessments were performed blinded to theBNP levels. Low exercise capacity was deﬁned as achieving
<5 METs on treadmill exercise.19
Patients were either referred for PMC or to continue annual
regular follow up assessments according to the symptomatic
status on exercise testing and the exercise capacity.
For group I patients, PMC was done after exclusion of left
atrial or left atrial appendage clots and conﬁrmation of MR
severity by trans-esophageal echocardiography.21,25
2.4. Statistical analysis
Baseline demographic and analytical information are
presented as absolute number (percentage for categorical vari-
ables). Comparison of categorical and continuous variables
between the 2 groups was performed using chi-square and
unpaired t-test, respectively. Correlations between variables
were calculated by Pearson correlation coefﬁcient. To evaluate
the ability of BNP to predict low exercise capacity and devel-
opment of symptoms on exercise, the area under the receiver-
operating characteristic (ROC) curve was used. An optimal
cutoff value was calculated from analyses of the ROC curve.
Statistical analysis was performed using SPSS for windows
(version 19 SSPS Inc, Chicago, IL, USA). All P values were
evaluated and a result of <0.05 was considered signiﬁcant. P
values <0.001 were considered highly signiﬁcant.
3. Results
3.1. Baseline demographic and echo-Doppler characteristics
As shown in Table 1, both study groups were comparable
regarding baseline demographic characteristics and
medications (beta-blockers, loop diuretics), (P> 0.05).
54.5% in-group I had AF compared to 59.4% in-group II,
P> 0.05. There was no statistically signiﬁcant difference
between the two groups regarding any of the studied baseline
echo-Doppler criteria apart from left atrial (LA) dimension
Table 3 Baseline BNP levels in group I versus group II; plus
pre and one week post balloon dilatation (PMC) in group I
patients.
Group I Group II P value
BNP level (pg/ml) (Baseline) 92 ± 12 40 ± 10 <0.001
BNP level (pg/ml) post-PMC 31 ± 9
P value <0.001
BNP: Brain Natriuretic Peptide; PMC: percutaneous mitral
commissurotomy.
Figure 1 Receiver-operating characteristic curve for BNP to
predict low exercise capacity and development of symptoms on
exercise.
Table 4 Correlation analysis of some studied variables (at
rest) and exercise–induced elevation of systolic pulmonary
artery pressure >60 mmHg.
Variable r P value
Age (year) 0.108 >0.05
MVA (cm2) 0.327 <0.01
LAD (cm) 0.285 <0.05
mPG (mmHg) 0.319 <0.01
BNP (pg/ml) 0.635 <0.001
MVA: mitral valve area; LAD: left atrial dimension; mPG: mean
pressure gradient; BNP: Brain Natriuretic Peptide.
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3.2. Treadmill exercise test (as shown in Table 2)
Peak exercise heart rate was not statistically signiﬁcant on
comparing both groups (139 ± 17.4 compared to 145 ± 19.5
b/m, respectively, P> 0.05). Peak-exercise SPAP was
72 ± 12, compared to 46 ± 13 mmHg respectively,
P< 0.001. Peak-exercise mean gradient across mitral valve
was 28 ± 9 compared to 20 ± 12 mmHg respectively,
P= 0.002.
3.3. BNP levels
As shown in Table 3, baseline BNP levels were signiﬁcantly
higher in group I patients compared to group II (92 ± 12
compared to 40 ± 10 pg/ml, respectively, P< 0.001). The
upper limit of the normal lab reference for BNPwas 42 pg/ml.20
In group I, all patients underwent PMC. The procedure was
successful in all patients. Procedural success was deﬁned as
post-procedure MVA P1.5 cm2 and MR severity <2/4 or a
50% gain in relation to the measured area before the proce-
dure.19 BNP levels one-week post balloon valvuloplasty
dropped signiﬁcantly compared to baseline values (92 ± 12
compared to 31 ± 9 pg/ml, P< 0.001).
As shown in Fig. 1, analysis of the receiver-operating
characteristic curve for BNP as a predictor of low exercise
capacity and development of symptoms on exercise showed
an area under the curve of 0.98 [conﬁdence interval 95%,
0.96–1.0], kappa measure of agreement 0.85, P< 0.001.
When using a BNP cut-off value of 55 pg/ml, derived from
the receiver-operating characteristic curve as a predictor of low
exercise capacity and development of symptoms on exercise,
sensitivity was 93.9%, speciﬁcity was 91.9%, positive predic-
tive value was 91.2% and negative predictive value was 94.4%.
Correlation analysis between some studied variables and
post-exercise elevation of systolic pulmonary artery pressure
>60 mmHg is shown in Table 4. There was a positive correla-
tion between resting mitral valve area (r= 0.327, P< 0.01),
left atrial dimension (r= 0.285, P< 0.05), resting mean trans-
mitral gradient (r= 0.319, P< 0.01), baseline BNP
level(r= 0.635, P< 0.001) and post-exercise elevation of
SPAP >60 mmHg.
4. Discussion
In this study, we demonstrated that in asymptomatic patients
with clinically signiﬁcant MS, a baseline BNP assessmentTable 2 Exercise treadmill test and post exercise echo-
Doppler results in both study groups.
Group I Group II P value
Peak PAP (mmHg) 72 ± 12 46 ± 13 <0.001
Mean MV gradient (mmHg) 28 ± 9 20 ± 12 0.002
LVEF (%) 69 ± 12.5 72 ± 11.3 0.43
Peak heart rate (b/m) 139 ± 17.4 145 ± 19.5 0.32
LVEF: left ventricular ejection fraction; MV: mitral valve; PAP:
pulmonary artery pressure.could predict symptomatic status on exercise and low exercise
capacity. A cut-off point for BNP that was concluded from the
ROC curve (55 pg/ml) was found to have a reasonable sensitiv-
ity and speciﬁcity. We found also a signiﬁcant positive correla-
tion between BNP levels and exercise induced elevation of
SPAP >60 mmHg.
Contrary to the 2008 American College of Cardiology/
American Heart Association (ACC/AHA) guidelines for man-
agement of valvular heart diseases [where PMC was class I
indication in asymptomatic moderate to severe MS (MVA
Potential use of BNP in asymptomatic MS 27361.5 cm2 with suitable valve morphology), if resting SPAP is
>50 mmHg, >60 mmHg on exercise or when patients have
poor exercise tolerance], ACC/AHA 2014 guidelines state that
although exercise-induced pulmonary hypertension does not
have a formal place in those guidelines, a rise in RV systolic
pressure to >60 mmHg to 70 mmHg should prompt the clini-
cian to carefully consider the patient’s symptoms.26,27
Rheumatic heart diseases are most prevalent in developing
countries where patients who need regular follow up and
proper risk stratiﬁcation may have limited access to echocardi-
ography or exercise testing. On the other hand, it is clear from
the currently available evidence that better risk stratiﬁcation of
asymptomatic patients with signiﬁcant valvular disease is still
required. Symptomatic status is totally subjective and some
patients may simply avoid symptoms by limiting their exertion
over years while others may get symptoms on mild exertion
due to noncardiac dyspnea or due to physical deconditioning.
A simple objective tool that could be used in regular follow up
of a subset of MS patients (asymptomatic with MVA 61.5 and
>1 cm2) and that could predict development of symptoms on
exercise would be clinically very helpful. A useful biomarker
would reﬂect disease severity, increase with progression of dis-
ease, reﬂect subclinical myocardial dysfunction, discriminate
between patients in whom symptoms do and do not develop
in the short to medium term, and be easily and reliably
measured.28
Natriuretic peptides (ANP, BNP, and NT-pro-BNP) have
been studied in MS patients in several trails29–31 and a correla-
tion between natriuretic peptide level and severity of mitral
stenosis and patients’ symptoms was found.
Sharma, et al. studied 30 patients with moderate to severe
MS versus 13 normal controls. They found that BNP was
higher in MS patients compared to controls (BNP 58 [34, 93]
vs. 16 [14, 25 pg/ml], P< 0.0001). They divided patients into
groups according to the BNP level (control, normal BNP,
BNP <84 pg/ml and BNP >84 pg/ml). Their results match
those of our study as they found an association between
BNP and development of symptoms on exercise, exercise
capacity, and SPAP >50 at rest or >60 mmHg on exercise.4
Our results agree with those of Kilickesmez, et al. who
found a correlation between NT pro-BNP level and exercise-
induced augmentation of pulmonary artery pressure in
patients with moderate to severe, asymptomatic or mildly
symptomatic mitral stenosis. They studied 41 asymptomatic
or mildly symptomatic moderate to severe mitral stenosis
patients versus 21 age and sex-matched control healthy
subjects. They found that the plasma concentrations of NT
pro-BNP levels were signiﬁcantly higher in patients with mitral
stenosis than in control subjects before and after exercise
(P< 0.001).They concluded that NT pro-BNP levels corre-
lated with functional class and echocardiographic ﬁndings in
patients with mitral stenosis and indicated exercise induced
augmentation of peak PAP >60 mmHg compared to control
subjects. They also found a signiﬁcant correlation between
NT Pro BNP and the left atrial dimension, right ventricular
end diastolic diameter, exercise duration, heart rate, rest, and
exercise pulmonary artery systolic pressure and after exercise
mitral valve mean gradient.32
We found that left atrial dimensions were larger in group I
compared to group II. This could explain the higher levels of
BNP in group I and augment the already available evidence
of BNP co-storage and secretion from the left atrium.7–10 Wefound that BNP levels dropped signiﬁcantly one week post bal-
loon valvuloplasty in group I patients. This drop could be
explained by the expected drop in the mean left atrial diameter,
pressure and also the expected drop in the pulmonary artery
pressure and subsequently the right ventricular pressure. After
PMC, pulmonary pressures fall soon because elevated pulmon-
ary vascular resistance is usually due to reactive vasoconstric-
tion rather than permanent histopathologic changes.33
Concordant with our results, a study done by Selcuk, et al.
found a signiﬁcant drop of NT pro-BNP post PMC.5 This
again could prove a causal relationship between natriuretic
peptides and severity of MS. Also, concordant with our results,
a study done by Shang, et al. found a signiﬁcant drop in the
BNP levels when pre and post percutaneous mitral balloon
valvuloplasty BNP levels were compared.6
We did not include patients with MVA<1 cm2 (very severe
MS, as deﬁned by ACC/AHA 2014 guidelines) where interven-
tion by PMC is justiﬁed regardless of symptomatic status if
valve scores were suitable.26
A cut-off point of 55 pg/ml for BNP to predict development
of symptoms on exercise in MS is lower than that set by the
ESC/Heart Failure guidelines to exclude heart failure as a
cause of dyspnea (100 pg/ml).34 This may be explained by
the source of BNP secretion (left atrium in MS where BNP
is co-secreted in addition to ANP), and the left ventricle in case
of left ventricular failure. On the other hand, Pizzaro, et al.
concluded a BNP cut-off value of P105 pg/ml to identify
asymptomatic MR patients at higher risk of developing heart
failure, LV dysfunction or death on mid-term follow-up17, a
cut-off value that was higher than that set by the current study.
This again could be explained by the source of BNP secretion
(both LA and LV in case of MR).
To the best of our knowledge, this is the ﬁrst study of BNP
assessment in asymptomatic signiﬁcant MS that (1) identiﬁed
patients who fulﬁlled intervention criteria set by the ESC,
and (2) assessed BNP level after PMC in the same study.
Moreover, this is the ﬁrst study to set a cutoff value for
BNP level that could predict low exercise capacity and devel-
opment of symptoms on exercise.
5. Suggestion for future research
Larger caliber studies recruiting more patients with an inten-
tion to validate the set cut-off BNP value that could predict
a justiﬁed intervention by PMC in patients with asymptomatic
signiﬁcant MS are strongly suggested. Further studies on the
same patients’ cohort may result in sufﬁcient evidence to
implement BNP use in regular follow up and decision making
in future guidelines. An interesting area of research would be
whether BNP cut-off value could be confounded be medica-
tions (e.g. loop diuretics) or arrhythmia as atrial ﬁbrillation.
6. Conclusion
Brain Natriuretic Peptide may be used as a risk stratiﬁcation
tool for asymptomatic patients with signiﬁcant mitral stenosis
whose resting echo-Doppler assessments do not meet criteria
for intervention. BNP may be used to identify an important
subset of patients with exercise-induced clinical and
echo-Doppler criteria that meet the contemporary guidelines
for intervention.
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